PR Newswire
08 May 2023, 20:30 GMT+10
![]() |
SAN FRANCISCO, HOUSTON and SINGAPORE, May 8, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at IMMUNOLOGY2023.
The company will present preclinical data for HMBD-011, an anti-VH4-34 antibody developed with Hummingbird Bioscience's Rational Antibody Discovery platform. In preclinical models, HMBD-011 effectively inhibits cold agglutination and clears VH4-34+ antibodies in circulation within 24 hours. HMBD-011 also mediates clearance of VH4-34+ cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
"HMBD-011 targets the small conserved conformational hydrophobic patch of VH4-34, which is challenging to target with traditional antibody discovery approaches. With its differentiated mechanism of action, HMBD-011 has the potential to address underlying disease pathology in lupus (systematic lupus erythematosus and cutaneous lupus erythematosus) and cold agglutinin disease," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. "We look forward to sharing the preclinical data for our novel anti-VH4-34 antibody and discussing therapeutic strategies with the immunology community."
IMMUNOLOGY2023
Poster Session Title: Innovations in the Manipulation of T Cells for Treating Autoimmune Diseases
Poster Session Date: Sunday May 14, 2023
Time: 14:30 - 15:45 EDT
Poster Board Number: P768
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. We are currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase 1 studies. At Hummingbird Bioscience, our commitment to rigorous science, teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, Twitter, and YouTube.
About HMBD-011
Developed with Hummingbird Bioscience's proprietary Rational Antibody Discovery (RAD) platform, HMBD-011 is an anti-VH4-34 antibody designed to target the small conformational hydrophobic patch of VH4-34. HMBD-011 selectively binds, blocks and depletes VH4-34+ autoantibodies and autoreactive VH4-34+ B cells, and has demonstrated efficacy in preclinical models. The differentiated mechanism of action of HMBD-011 has the potential to selectively target disease pathogenesis in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and cold agglutinin disease (CAD), versus a broad B cell depletion and inhibition approach that risks compromising normal immune functions.
Get a daily dose of Philippine Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Philippine Times.
More InformationLOUISVILLE, Kentucky: Two horses that succumbed to their injuries at Churchill Downs have become the 11th and 12th fatalities over ...
FREMONT, California: Brain implant company Neuralink announced that it has received approval from US regulators to begin human brain implant ...
JEFFERSONVILLE, Indiana: Randy Lankford, owner of Lankford Funeral Home and Family Center in Jeffersonville, Indiana, has pleaded guilty to more ...
DENVER, COLORADO: A federal judge has ruled that a rural Colorado school district can ban a high school student from ...
ZURICH, Switzerland: In one of the largest legal awards ever against Credit Suisse, the bank was ordered to pay $926 ...
DETROIT, Michigan: Amid broader global concerns over semiconductor chip supplies, sanctions and national security, Chinese commerce minister Wang Wentao said ...
PORTLAND, Maine: Fishermen in the US's only commercial-scale fishing industry for valuable baby eels, called elvers, have recorded a productive ...
LAS VEGAS, Nevada: A bill was introduced in the Nevada Legislature to provide the Oakland Athletics up to $380 million ...
WASHINGTON D.C.: Due to one of the tightest labor markets in decades, teenagers, who have been vital for filling summer ...
NEW YORK, New York - Republicans were in uproar Tuesday over the deal hammered out by President Joe Biden and ...
DETROIT, Michigan: After Ford Motor Co announced an agreement with Tesla to allow autos to be charged using the Tesla ...
WARSAW, Poland: Plans are underway in Poland to gradually raise the minimum wage twice in 2024. The wage plan has ...